We are a leading manufacturer of contrast agents for magnetic resonance and computer tomography. Radiologists in over 50 countries use our products for diagnostic imaging. A particular focus lies on gadolinium-free alternatives that may offer advanced imaging possibilities, especially for individuals with kidney impairment.
By pushing the boundaries of MRI imaging agents, we aim to save patients’ lives through earlier cancer detection, without compromising patient safety. At Sanochemia, our target is set to become a global leader in innovative MRI niches. With our evolving portfolio, we are positioned to realize growth and make a significant impact in diagnostic imaging.
In Austria, we develop, produce and distribute some of the most established imaging agents as Sanochemia branded products. Our products help physicians make efficient therapeutic decisions for patients.
With contract manufacturing of sterile and low-bioburden liquids as well as APIs, we offer in-depth expertise in the field of drug product and API production. As a full-service provider, we also support with GMP services.
By developing, manufacturing and distributing pharmaceutical specialities, Sanochemia has been contributing to people’s health for over 30 years.We focus on setting new standards in the quest for excellence in contract manufacturing. Our goal is to produce high quality pharmaceutical specialties for physicians and partner companies.
Our production facilities and train concept enable us to respond quickly to requirements and deliver the highest quality in accordance with cGMP requirements.
Our highly qualified team is on hand to provide a comprehensive range of technical, procedural and regulatory services.
We focus on quality and ensure that GMP-compliant production and a high degree of flexibility complement each other.
The products are filled, labeled and packaged in various sizes – with maximum flexibility and focus on individual customer needs.
In-house research and development capacities and an attractive production site in the middle of Europe, in Neufeld an der Leitha, form the ideal basis for future developments. Our employees are the heart of Sanochemia and put a lot of experience, passion and commitment into the manufacturing of our products.
We focus on the development, production and distribution of pharmaceuticals – so-called Finished Dosage Forms – and active ingredients – Active Pharmaceutical Ingredients – for specific medical applications. The needs of patients, customers and healthcare professionals provide us with the impetus for new developments. Together with a network of partnerships, we evaluate new products for the future.
By pushing the boundaries of MRI imaging agents, we aim to save patients’ lives through earlier cancer detection, without compromising patient safety. At Sanochemia, our target is set to become a global leader in innovative MRI niches. With our evolving portfolio, we are positioned to realize growth and make a significant impact in diagnostic imaging.
“Together for a brighter life” means more to us than just a slogan, but rather a statement about making the invisible visible and ensuring optimal therapeutic decisions for patients across the globe.
We are appreciative and authentic. We see joint development with partner companies and employees as an important cornerstone of our entrepreneurial activities. We believe that the best products and the highest quality are the result of passion, cooperation and commitment of each individual. This enables us to go the “extra mile” and has created a reputation as a reliable partner with great potential for the future.
The foundation for this is a team of dedicated and highly competent people who walk the path together with us and live first-class product quality, flexibility and customer orientation every day.
The registration initiative launched by Sanochemia Pharmazeutika in 2021, together with the continuously increasing market demand, has led to a record volume of orders.
Read moreSanochemia Pharmazeutika secures exclusive licensing rights to a new MRI contrast agent based on ferumoxtran, that is in an advanced pivotal trial in clinical phase III and may be used to detect the smallest lymph node metastases in prostate cancer patients. The product is already deployed in the Netherlands within an authorized Named-Patient-Use-Program (Artsenverklaring).
Read moreSanochemia Pharmazeutika is strengthening its position in the field of medical imaging with an exclusive product license for a MRI contrast agent based on iron-containing nanoparticles under the brand name Resotran®.
Read more
